稳字当头:恒瑞医药换届稍欠锐气

财中TMT
Mar 11

公司换届平稳落地,有助于公司维持战略定力,但接班人梯队缺失、治理机制保守,已为长期发展埋下隐患。创新锐气或在求稳中被削弱,更可能令恒瑞医药错失关键转型窗口期。作者/李熹编辑/赵寒3月2日,恒瑞医药(600276.SH/01276.HK)换届最终落定,第十届董事会提名公告显示,孙飘扬领衔的核心执行董事团队整体留任,仅一名独立董事调整。本次提名经11名董事全票通过,执行董事候选人依旧是孙飘扬、戴洪斌、...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10